Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 16.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,135 shares of the biotechnology company’s stock after purchasing an additional 1,168 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in United Therapeutics were worth $953,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Yorktown Management & Research Co Inc acquired a new stake in shares of United Therapeutics during the 3rd quarter worth about $281,000. Meiji Yasuda Asset Management Co Ltd. acquired a new stake in shares of United Therapeutics during the 3rd quarter worth about $233,000. Pacer Advisors Inc. increased its position in shares of United Therapeutics by 6.9% during the 3rd quarter. Pacer Advisors Inc. now owns 7,188 shares of the biotechnology company’s stock worth $842,000 after purchasing an additional 461 shares during the last quarter. Thompson Siegel & Walmsley LLC increased its position in shares of United Therapeutics by 1.6% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 590,382 shares of the biotechnology company’s stock worth $69,186,000 after purchasing an additional 9,271 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its position in shares of United Therapeutics by 221.6% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 7,073 shares of the biotechnology company’s stock worth $828,000 after purchasing an additional 4,874 shares during the last quarter. 99.94% of the stock is owned by hedge funds and other institutional investors.

UTHR has been the subject of several research reports. ValuEngine downgraded United Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 8th. Oppenheimer reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Friday, September 8th. Zacks Investment Research downgraded United Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. TheStreet downgraded United Therapeutics from a “b-” rating to a “c” rating in a research report on Friday, September 29th. Finally, HC Wainwright reissued a “hold” rating and set a $95.00 price objective on shares of United Therapeutics in a research report on Thursday, October 26th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. United Therapeutics has a consensus rating of “Hold” and an average target price of $136.10.

In related news, CEO Martine A. Rothblatt sold 1,232 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $133.32, for a total transaction of $164,250.24. Following the completion of the sale, the chief executive officer now owns 2,301 shares in the company, valued at $306,769.32. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,241 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $128.95, for a total value of $160,026.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,900 shares of company stock valued at $2,919,517. 7.80% of the stock is owned by company insiders.

United Therapeutics Corporation (NASDAQ UTHR) opened at $133.32 on Monday. The company has a market capitalization of $5,760.90, a PE ratio of 11.76 and a beta of 1.42. United Therapeutics Corporation has a 52-week low of $112.01 and a 52-week high of $169.89.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.23 earnings per share. research analysts anticipate that United Therapeutics Corporation will post 12.45 EPS for the current fiscal year.

WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/04/zurcher-kantonalbank-zurich-cantonalbank-has-953000-stake-in-united-therapeutics-corporation-uthr.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.